GEF-H1, Human, mAb B4/7
The monoclonal antibody B4/7 recognizes human and canine guanine nucleotide exchange factor H1 (GEF-H1). GEFH1 is an ~110 kDa protein belonging to the Dbl family of proto-oncogenes. GEF-H1 can activate the small GTPase RhoA, but not Rac1 or Cdc42. Rho family GTPases are central regulators of epithelial tight junctions and the cytoskeleton. GEF-H1 can associate with different cytoskeletal structures, namely microtubules and the actin cytoskeleton. It has also been proposed to mediate crosstalk between the two types of filaments.
Localization of GEF-H1 differs between cell types. In MRC-5 fibroblast cells, GEF-H1 localizes to stress fibers. In epithelial cells, GEF-H1 is associated with apical tight junctions and involved in regulating paracellular permeability of small hydrophilic tracers. Furthermore, its subcellular localization changes in mitotic cells, where endogenous GEF-H1 is concentrated at mitotic spindles. GEF-H1 is capable of binding to the F-actin binding junctional adaptor cingulin. Binding to cingulin inhibits GEF-H1 and results in the downregulation of RhoA and inhibition of G1/S phase transition. In low confluent cultured cells, the localization of GEF-H1 is predominantly cytoplasmic. With increasing density of the cells, free GEF-H1 is sequestered at the tight junctions by cingulin.
GEF-H1 is part of the signaling pathway connecting epithelial polarity with the cell cycle, and as such involved in oncogenesis.
F: Cells were either fixed with methanol at -20 °C or with 3% PFA followed by permeabilization with Triton X-100.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA